However, despite targeting different epitopes of the CD20 receptor than rituximab, newer antibodies, such as ofatumumab and obinutuzumab, have not shown any significant improvement over rituximab in DLBCL [24,25]. The gene discussed is MS4A1; the disease is diffuse large B-cell lymphoma.